Characterization of an MR‐compatible motion platform for quality assurance of motion‐compensated treatments on the 1.5 T MR‐linac.
Saved in:
| Title: | Characterization of an MR‐compatible motion platform for quality assurance of motion‐compensated treatments on the 1.5 T MR‐linac. |
|---|---|
| Authors: | Oolbekkink, Stijn1 (AUTHOR) s.oolbekkink@umcutrecht.nl, Borman, Pim T. S.1 (AUTHOR), Wolthaus, Jochem W. H.1 (AUTHOR), van Asselen, Bram1 (AUTHOR), van Lier, Astrid L. H. M. W.1 (AUTHOR), Dunn, Stephanie2 (AUTHOR), Koenig, Grant R.2 (AUTHOR), Hartman, Nick2 (AUTHOR), Kheirkhah, Niusha2 (AUTHOR), Raaymakers, Bas W.1 (AUTHOR), Fast, Martin F.1 (AUTHOR) |
| Source: | Medical Physics. May2025, Vol. 52 Issue 5, p3391-3397. 7p. |
| Subjects: | Quality assurance, Magnetic resonance imaging, Medical dosimetry |
| Abstract: | Background: Novel motion‐compensated treatment techniques on the MR‐linac can address adverse intra‐fraction motion effects. These techniques involve beam gating or intra‐fraction adaptations of the treatment plan based on real‐time magnetic resonance imaging (MRI) performed during treatment. For quality assurance (QA) of these workflows, a multi‐purpose motion platform is desirable. This platform should accommodate various phantoms, enabling multiple QA workflows. Purpose: This study aims to evaluate the new IBA QUASAR Motion MR Platform for use in the 1.5 T MR‐linac. Methods: The motion platform was assessed for several magnetic resonance (MR) characteristics, including spurious noise generation and B0&B1 homogeneity. In addition, the motion platform's motion accuracy and beam attenuation were assessed. An application was shown with a ScandiDos Delta4 Phantom+ MR demonstrating patient‐specific plan QA of gated treatments using time‐resolved dosimetry that includes motion based on a patient's respiratory motion trace. Results: All MR characterization measurements were within the set tolerances for MRI QA. The motion platform motion accuracy showed excellent agreement with the reference, with a standard deviation of the amplitude of 0.01 mm (20 kg load) for the motor's self‐estimated positions and 0.22 mm (no load) for the images acquired with the electronic portal imager. Beam attenuation was found to be 11.8%. The combination of the motion platform and Delta4 demonstrated motion‐included dosimetry at high temporal and spatial resolutions. Motion influenced the measured dose in non‐gated treatments by up to −20.1%, while gated deliveries showed differences of up to −1.7% for selected diodes. Conclusion: The motion platform was found to be usable in a 1.5 T magnetic field, and for all MR characterization experiments, no influence from the motion platform was observed. This motion platform enables to perform motion‐included QA, with a measurement device of choice. [ABSTRACT FROM AUTHOR] |
| Copyright of Medical Physics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Novel motion‐compensated treatment techniques on the MR‐linac can address adverse intra‐fraction motion effects. These techniques involve beam gating or intra‐fraction adaptations of the treatment plan based on real‐time magnetic resonance imaging (MRI) performed during treatment. For quality assurance (QA) of these workflows, a multi‐purpose motion platform is desirable. This platform should accommodate various phantoms, enabling multiple QA workflows. Purpose: This study aims to evaluate the new IBA QUASAR Motion MR Platform for use in the 1.5 T MR‐linac. Methods: The motion platform was assessed for several magnetic resonance (MR) characteristics, including spurious noise generation and B0&B1 homogeneity. In addition, the motion platform's motion accuracy and beam attenuation were assessed. An application was shown with a ScandiDos Delta4 Phantom+ MR demonstrating patient‐specific plan QA of gated treatments using time‐resolved dosimetry that includes motion based on a patient's respiratory motion trace. Results: All MR characterization measurements were within the set tolerances for MRI QA. The motion platform motion accuracy showed excellent agreement with the reference, with a standard deviation of the amplitude of 0.01 mm (20 kg load) for the motor's self‐estimated positions and 0.22 mm (no load) for the images acquired with the electronic portal imager. Beam attenuation was found to be 11.8%. The combination of the motion platform and Delta4 demonstrated motion‐included dosimetry at high temporal and spatial resolutions. Motion influenced the measured dose in non‐gated treatments by up to −20.1%, while gated deliveries showed differences of up to −1.7% for selected diodes. Conclusion: The motion platform was found to be usable in a 1.5 T magnetic field, and for all MR characterization experiments, no influence from the motion platform was observed. This motion platform enables to perform motion‐included QA, with a measurement device of choice. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 00942405 |
| DOI: | 10.1002/mp.17632 |
